JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain. It operates in three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
IPO Year:
Exchange: NASDAQ
Website: janone.com
4 - JanOne Inc. (0000862861) (Issuer)
4 - JanOne Inc. (0000862861) (Issuer)
4 - JanOne Inc. (0000862861) (Issuer)
4 - JanOne Inc. (0000862861) (Issuer)
-The board has approved a strategic review of the biotech assets and ALT5 Sigma being the core focus going forward- -The company is intending a name and stock symbol change to reflect this decision- LAS VEGAS, July 10, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value through a visionary strategic realignment, entailing a redeployment of biotech assets and a change of its name. The plan, unanimously approved by the company's board and following the May acquisi
The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be i
LAS VEGAS, Dec. 7, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO). The agreement with LSU Health Shreveport, along with other intellectual property relating to TSPO's role in treating meth use disorder (MUD), provides JanOne Inc. with an opportunity to identify new drugs to enhance TSPO activity, and by doing so, reducing craving for meth. This new strategy for treating MUD w
LAS VEGAS, NV / ACCESSWIRE / January 15, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a prominent innovator in the cryptocurrency sector, is pleased to announce a partnership with Hashtag Influencer, an advanced AI-powered SocialFi platform. This collaboration aims to enhance the influencer marketing landscape by enabling influencers in the gig economy to seamlessly and compliantly accept cryptocurrency payments for advertising deals with brands through social media platforms such as Instagram, Facebook, YouTube, and LinkedIn."While much attention has been given to the adoption of blockchain by traditional institutions, collaborating with innovators such as Hashtag Influencer-a forthcoming A
Finalist to present at RESI JPM IPC and attend the Nasdaq Opening Bell Ceremony on January 13 LAS VEGAS, NV / ACCESSWIRE / January 10, 2025 / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025, in San Francisco, California. Alyea is developing innovative, actionable solutions intended to help end the opioid crisis with its lead asset ("JAN123"), a novel formulation of Low Dose Naltrexone ("LDN"), preparing for its pivotal Phase III study. Having already been granted Orphan Drug designa
LAS VEGAS, NV / ACCESSWIRE / January 9, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced its participation in the upcoming iFX EXPO Dubai.ALT5 will be exhibiting through the three days of the show at the Dubai World Trade Centre, providing product demonstrations, solutions and general information to many of the 7,000+ attendees starting January 14th in booth #26.iFX EXPO Dubai 2025 is the ultimate meeting place for brokers, affiliates, traders, investors, and tech- and service-providers who are looking to succeed in the MENA
All resolutions were approved LAS VEGAS, NEVADA / ACCESSWIRE / December 18, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a leading fintech firm offering next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safekeeping of digital assets, today announced that all proposed binding resolutions were approved at its 2024 Annual General Meeting (AGM).Shareholders re-elected Ron Pitters, Richard D. Butler, Tony Isaac, John Bitar, and Nael Hajjar to the Board of Directors. Additionally, current CEO Peter Tassiopoulos was also elected to the Board."As we reflect on a transformative 2024, we are proud to have achieved re
Record quarter for ALT5 with Q3 revenue of $4.94 millionNew customer onboarding strong in Q3 and continuing into Q4Launching additional capabilities for Alt5 Prime and Alt5 Pay in Q4 2024 and Q1 2025LAS VEGAS, NV / ACCESSWIRE / November 12, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced financial results for its third fiscal quarter ended September 28, 2024."ALT5 Sigma's fintech segment delivers record performance in Q3, marking the first full quarter since the completion of the acquisition. We are
LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, is pleased to announce the appointment of Mr. Ron Pitters to its Board of Directors."We are thrilled to welcome industry veteran, Ron Pitters, to our Board. With a unique blend of experience in both traditional finance and disruptive blockchain technologies, Ron brings invaluable insights. His proven track record, spanning from startups to multinational corporations, makes him a fantastic addition to our team,"
Premier Event to Showcase Growth Companies and Foster High-Level Investor EngagementLAS VEGAS, NV / ACCESSWIRE / October 30, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), is proud to announce its participation in Spartan Capital Securities, LLC's inaugural investor conference on November 4th at the prestigious Pierre Hotel in New York.This participation aligns with our commitment to engage with industry leaders and investors. Our presentation will offer insight into our company's growth strategy and market position.Presenting Company Brief Description.Vay Tham, ALT5's CRO commented, "We are pleased to be invited and to present at Spartan Capital's inaugural investor conference. This event pro
LAS VEGAS, NV / ACCESSWIRE / October 23, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced their participation in the upcoming Money20/20 Las Vegas conference.ALT5 will be exhibiting through the 4 days of the conference at the The Venetian Resort, Las Vegas providing product demonstrations, solutions and general information to many of the 12,000+ attendees starting October 27th in booth #11713.Money20/20 USA is the world's biggest, most influential gathering of the global money ecosystem including banks, payments, tech, startu
LAS VEGAS, NV / ACCESSWIRE / October 9, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for September 2024.According to the company, ALT5's transaction volume exceeded US$240 million for the month of September 2024, which represents a year-over-year increase of approximately 151% from the $97 million recorded in September 2023. ALT5's year-to-date transaction volume is approximately $1.5 billion, with Q3 at over $600 million, representing a record quarter for transaction volume.Vay Tham, CRO of ALT5 Sig
LAS VEGAS, July 12, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on fintech and healthcare, confirmed today that, as of market open on Monday, July 15, 2024, the Company's new name will be "ALT5 Sigma Corporation" and its Nasdaq common stock ticker symbol will change to "ALTS". This will replace the Company's current ticker symbol "JAN". Further, the Company's website address will change from "janone.com" to "alt5sigma.com." The Company's change of name, ticker symbol, and website address aligns with the Company's realignment to
8-K - ALT5 Sigma Corp (0000862861) (Filer)
8-K - JanOne Inc. (0000862861) (Filer)
424B5 - JanOne Inc. (0000862861) (Filer)
8-K/A - JanOne Inc. (0000862861) (Filer)
8-K - JanOne Inc. (0000862861) (Filer)
8-K - JanOne Inc. (0000862861) (Filer)
424B5 - JanOne Inc. (0000862861) (Filer)
8-K - JanOne Inc. (0000862861) (Filer)
8-K - JanOne Inc. (0000862861) (Filer)
424B5 - JanOne Inc. (0000862861) (Filer)
SC 13G/A - JanOne Inc. (0000862861) (Subject)
SC 13G - JanOne Inc. (0000862861) (Subject)
SC 13G/A - JanOne Inc. (0000862861) (Subject)
SC 13G/A - JanOne Inc. (0000862861) (Subject)
SC 13D - JanOne Inc. (0000862861) (Subject)
SC 13G - JanOne Inc. (0000862861) (Subject)
SC 13G - JanOne Inc. (0000862861) (Subject)
LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, is pleased to announce the appointment of Mr. Ron Pitters to its Board of Directors."We are thrilled to welcome industry veteran, Ron Pitters, to our Board. With a unique blend of experience in both traditional finance and disruptive blockchain technologies, Ron brings invaluable insights. His proven track record, spanning from startups to multinational corporations, makes him a fantastic addition to our team,"
LAS VEGAS, June 26, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary. Mr. Tham brings extensive experience in capital markets, particularly in technology sectors, spanning over 25 years. His career includes roles in research, investment banking, and finance, notably and most recently as Managing Director and Head of Technology Investment Banking at PI Financial Corp. (Ventum Financial).
LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in drug addiction. Tony Isaac, President and Chief Executive Officer of JanOne, commented, "JanOne's mission is to develop non-addictive medications to treat diseases that cause severe pain, thereby m